मूलभूत आँकड़े
| CIK | 1757097 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Centogene N.V.
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES Exchange ACT OF 1934 For the month of December 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES Exchange ACT OF 1934 For the month of December 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| December 5, 2024 |
Exhibit 99.1 CENTOGENE Announces Voting Results of Extraordinary General Meeting Approval of All Resolutions, Including Announced Transaction With Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, December 4, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegener |
|
| November 19, 2024 |
Exhibit 99.2 1 82043617 M 55971637 / 7 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Shareholder"). DECLARES AS FOLLOWS 1. The Shareholder registers for the extraordinary general meeting of shareholders of Centogene N.V. (the "Company") to be held on December 4, 2024 at 2:00 p.m. CET at the offices of NautaDutilh N.V., B |
|
| November 19, 2024 |
1 PROPOSED ARTICLES OF ASSOCIATION Exhibit 99.3 1 PROPOSED ARTICLES OF ASSOCIATION DEFINITIONS AND INTERPRETATION Artikel 1 1.1 In these articles of association the following definitions shall apply: Article An article of these articles of association. CEO The Company's chief executive officer. Chairman The chairman of the Supervisory Board. Company The company to which these articles of association pertain. DCC The Dutch Civil Cod |
|
| November 19, 2024 |
Exhibit 99.1 1 CONVENING NOTICE This is the convening notice for the extraordinary general meeting of shareholders of Centogene N.V. (the "Company") to be held on December 4, 2024 at 2:00 p.m. CET at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "EGM"). The agenda for the EGM is as follows: 1. Opening 2. Approval of the envisaged sale and transfer of |
|
| November 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES Exchange ACT OF 1934 For the month of November 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES Exchange ACT OF 1934 For the month of November 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| November 13, 2024 |
Exhibit 99.3 Execution Version DATED 12 November 2024 GENOMICS INNOVATIONS COMPANY LIMITED as Lender and CENTOGENE GMBH as Borrower SHORT TERM LOAN FACILITY AGREEMENT Al-Tatweer Towers, 7th Floor, Tower 1 King Fahad Highway PO Box 17411 Riyadh 11484, Saudi Arabia www.lw.com Execution Version of the Short Term Loan Facility Agreement between Genomics Innovations Company Limited and Centogene GMBH T |
|
| November 13, 2024 |
Exhibit 99.4 Execution Version DATED 12 November 2024 CENTOGENE GMBH (as Pledgor) and GENOMICS INNOVATIONS COMPANY LIMITED (as Pledgee) Receivables pledge AGREEMENT Al-Tatweer Towers, 7th Floor, Tower 1 King Fahad Highway PO Box 17411 Riyadh 11484, Saudi Arabia www.lw.com Execution Version of the Recievables Pledge Agreement between Centogene GMBH and Genomics Innovations Company Limited CONTENTS |
|
| November 13, 2024 |
Exhibit 99.2 IRREVOCABLE undertaking This IRREVOCABLE UNDERTAKING (the “Agreement”) is entered into on November [●], 2024 between: 1. [name], a legal entity under the laws of [jurisdiction] (the “Shareholder”); 2. Centogene N.V., a public company under the laws of the Netherlands (the “Company” and, together with the Shareholder, the “Parties” and each of them a “Party”). WHEREAS A. On [the date h |
|
| November 13, 2024 |
CENTOGENE N.V. Charme IV Share PURCHASE AGREEMENT DATED 12 november 2024 Exhibit 99.1 CLIFFORD CHANCE LLP Strictly private and confidential CENTOGENE N.V. and Charme IV Share PURCHASE AGREEMENT DATED 12 november 2024 CONTENTS Clause Page 1. Definitions and Interpretation 3 2. Sale, Purchase and transfer of the Shares and Shareholder Loans 3 3. Purchase Price, Reimbursment of costs and Payment 4 4. Conditionality 7 5. Closing 9 6. Ordinary Course of Business 10 7. Acces |
|
| November 13, 2024 |
CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners Exhibit 99.6 PRESS RELEASE CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, November 13, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (OTC: CNTGF) (“CENTOGENE” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has concluded its st |
|
| November 13, 2024 |
FORBEARANCE AGREEMENT, CONSENT AND FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 99.5 FORBEARANCE AGREEMENT, CONSENT AND FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FORBEARANCE AGREEMENT, CONSENT AND FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of November 12, 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxfo |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| October 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| October 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| September 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A (Amendment No. 1) REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal execu |
|
| September 26, 2024 |
Exhibit 99.1 September 19, 2024 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 United States Ladies and Gentlemen: We have read Item 304 of Centogene N.V.’s Form 6-K to be filed on September 19, 2024, and are in agreement with the statements contained in the first and third paragraphs therein. We have no basis to agree or disagree with other statements of the Company co |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicat |
|
| September 25, 2024 |
CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology Exhibit 99.1 CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology · Rostock International Parkinson's Disease (ROPAD) Study demonstrates a significant link between the RAB32 gene variant and Parkinson's disease, further supporting recent findings · Data from over subcohort of 3,350 patients shows that the RAB32 mutation is over 100 times more prevalent in Par |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicat |
|
| September 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicat |
|
| August 20, 2024 |
Exhibit 99.2 Service Agreement Centogene N.V. Thomas Wiedermann Dated 13 August 2024 This agreement is made on 13 August 2024 Parties (1) Centogene N.V., a public limited company incorporated under the laws of the Netherlands, with its registered seat in Amsterdam, the Netherlands, and having its office address at Am Strande 7, (18055) Rostock, Germany, and registered with the trade register of th |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate b |
|
| August 20, 2024 |
INDEMNIFICATION AGREEMENT Thomas Wiedermann as the Indemnitee Centogene N.V. as the Company Exhibit 99.3 INDEMNIFICATION AGREEMENT between Thomas Wiedermann as the Indemnitee and Centogene N.V. as the Company 2 TABLE OF CONTENTS 1 DEFINITIONS AND INTERPRETATION 3 1.1 Definitions 3 1.2 Interpretation 4 2 INDEMNIFICATION AND INSURANCE 5 2.1 Entitlement to indemnification 5 2.2 Advancements 5 2.3 No Claim by Company or subsidiaries 6 2.4 Limitations 6 2.5 Determination of entitlement to ind |
|
| August 20, 2024 |
Exhibit 99.1 Manager-Leasing contract CRO between Centogene GmbH Am Strande 7 18055 Rostock Germany hereinafter: „Client“ or „Centogene GmbH“ or „CNTG“ and: Atreus Interim Management GmbH Landshuter Allee 8 80637 Munich Germany hereinafter: „Contractor“ or „Atreus“ together hereinafter: the „Parties“ and: Centogene N.V. Am Strande 7 18055 Rostock Germany hereinafter: „Centogene N.V.“ Recitals As a |
|
| August 8, 2024 |
CENTOGENE Receives Delisting Notice From Nasdaq Exhibit 99.1 CENTOGENE Receives Delisting Notice From Nasdaq CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, August 07, 2024 (GLOBE NEWSWIRE) - Centogene N.V., the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate b |
|
| August 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate b |
|
| August 1, 2024 |
Exhibit 99.1 CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors · Initial data from largest international Parkinson’s disease patient cohort shows approximately 90% of these genetically confirmed patients had variants in the LRRK2 or GBA1 genes, making these individuals potential candidates to be included in gene-targeted trials · The Rost |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by |
|
| June 20, 2024 |
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development Exhibit 99.1 C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development TUCSON, Ariz., CAMBRIDGE, Mass., and ROSTOCK, Germany and BERLIN, June 20, 2024 - Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| May 31, 2024 |
CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting Exhibit 99.1 CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s 2024 Annual General M |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| May 15, 2024 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kim Stratton, certify that: 1.I have reviewed this Annual Report on Form 20-F of Centogene N.V.; 2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the ci |
|
| May 15, 2024 |
Exhibit 99.3 EXECUTION VERSION 12 May 2024 PHARMACEUTICAL INVESTMENT COMPANY and CENTOGENE N.V. SHARE PURCHASE AGREEMENT related to GENOMICS INNOVATIONS COMPANY LIMITED CONTENTS Clause Page 1. DEFINITIONS AND INTERPRETATION 3 2. SALE OF SHARES 8 3. CONSIDERATION 8 4. CONDITIONS 8 5. COMPLETION 9 6. Seller Call Option 9 7. WAIVER under jVa 10 8. Seller WARRANTIES 10 9. Purchaser Warranties 10 10. S |
|
| May 15, 2024 |
Exhibit 99.3 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on May 31, 2024 at 11.00 a.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Extension of the period for drawing up the Dutch statutor |
|
| May 15, 2024 |
AMENDMENT TO THE AWARD AGREEMENT Exhibit 4.34 AMENDMENT TO THE AWARD AGREEMENT THIS AGREEMENT IS MADE ON 20 JUNE 2023 BETWEEN 1. Jose Miguel Coego Rios, born on 22 August 1973 (the "Participant"); and 2. Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam (address: Am Strande 7, 18055 Rostock, Germany, trade register number: 72822872) (the "Company"). Each a "Party" and together the "Pa |
|
| May 15, 2024 |
AMENDMENT TO SECOND REGISTRATION RIGHTS AGREEMENT Exhibit 99.7 Execution version AMENDMENT TO SECOND REGISTRATION RIGHTS AGREEMENT THIS AMENDMENT TO SECOND REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made and entered into as of May 12, 2024, by and between Centogene N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Borrower”), and Pharmaceutical Investment Company, a |
|
| May 15, 2024 |
LIMITED WAIVER, CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 99.8 LIMITED WAIVER, CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS LIMITED WAIVER, CONSENT AND FOURTH AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of May 12, 2024, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collater |
|
| May 15, 2024 |
Exhibit 99.1 Execution Version DATED April 23, 2024 CENTOGENE GMBH And PHARMACEUTICAL INVESTMENT COMPANY KSA RECEIVABLES TRANSFER AGREEMENT Al-Tatweer Towers, 7th Floor, Tower 1 King Fahad Highway P.O. Box 17411 Riyadh 11484, Saudi Arabia www.lw.com TABLE OF CONTENTS Clause Page 1. DEFINITIONS AND INTERPRETATION 1 2. TRANSFER OF KSA RECEIVABLES 7 3. PROTECTION OF INTERESTS 8 4. REPRESENTATIONS, WA |
|
| May 15, 2024 |
FIRST AMENDMENT TO LOAN AGREEMENT Exhibit 4.26 Execution Version FIRST AMENDMENT TO LOAN AGREEMENT THIS FIRST AMENDMENT TO LOAN AGREEMENT (this “Amendment”) is made and entered into as of April 23, 2024, by and among CENTOGENE N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Borrower”), and PHARMACEUTICAL INVESTMENT COMPANY, a closed joint stock company inco |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| May 15, 2024 |
LONG-TERM INCENTIVE PLAN CENTOGENE N.V. Exhibit 4.37 LONG-TERM INCENTIVE PLAN CENTOGENE N.V. INTRODUCTION Article 1 1.1This document sets out the Company's long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2The main purposes of this Plan are: 1. to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote the growth |
|
| May 15, 2024 |
Exhibit 4.32 Execution Version GENOMICS INNOVATIONS COMPANY LIMITED (“Company”) and CENTOGENE N.V. (“NV”) dated [***] 2023 TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY LICENSE AGREEMENT TABLE OF CONTENTS Clause Page 1. DEFINITIONS; INTERPRETATION 2 2. LICENSE GRANTS AND ASSOCIATED RIGHTS AND RESTRICTIONS 3 3. TECHNOLOGY TRANSFER AND USE OF DATA 5 4. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTION AND |
|
| May 15, 2024 |
Exhibit 99.4 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on May 31, 2024 at 11.00 a.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amst |
|
| May 15, 2024 |
WRITTEN RESOLUTIONS OF THE MANAGEMENT BOARD OF CENTOGENE N.V. DATED 15, MAY 2024 Exhibit 99.5 WRITTEN RESOLUTIONS OF THE MANAGEMENT BOARD OF CENTOGENE N.V. DATED 15, MAY 2024 Resolutions of the management board (the "Management Board") of Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam, with address: Am Strande 7, 18055 Rostock, Germany, and trade register number: 72822872 (the "Company"). WHEREAS A. The undersigned constitute th |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| May 15, 2024 |
SECOND AMENDMENT TO LOAN AGREEMENT Exhibit 99.6 Execution version PRIVILEGED & CONFIDENTIAL SECOND AMENDMENT TO LOAN AGREEMENT THIS SECOND AMENDMENT TO LOAN AGREEMENT (this “Second Amendment”) is made and entered into as of May 12, 2024G., by and among CENTOGENE N.V., a public company with limited liability (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Borrower”), and PHARMACEUTICAL INVESTMENT COMPANY |
|
| May 15, 2024 |
Exhibit 4.27 Execution Draft DATED April 23, 2024 CENTOGENE GMBH And PHARMACEUTICAL INVESTMENT COMPANY KSA RECEIVABLES TRANSFER AGREEMENT Al-Tatweer Towers, 7th Floor, Tower 1 King Fahad Highway P.O. Box 17411 Riyadh 11484, Saudi Arabia www.lw.com 1 CONTENTS Clause Page 1. DEFINITIONS AND INTERPRETATION 3 2. TRANSFER OF KSA RECEIVABLES 8 3. PROTECTION OF INTERESTS 9 4. REPRESENTATIONS, WARRANTIES |
|
| May 15, 2024 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-234551) pertaining to the Centogene N.V. Long-Term Incentive Plan of our report dated May 15, 2024, with respect to the consolidated financial statements of Centogene N.V. included in this Annual Report (Form 20-F) for the year ended Dec |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| May 15, 2024 |
AMENDMENT TO THE SERVICES AGREEMENT Kim Stratton as the Officer Centogene N.V. as the Company Exhibit 4.35 Execution copy AMENDMENT TO THE SERVICES AGREEMENT between Kim Stratton as the Officer and Centogene N.V. as the Company 1 AMENDMENT TO THE SERVICES AGREEMENT THIS AMENDMENT AGREEMENT IS MADE ON June 12, 2023, BETWEEN 1. Kim Stratton, born on 9 July 1962 (the "Officer"); and 2. Centogene N.V., a public company (naamloze vennootschap), having its corporate seat in Amsterdam (address: A |
|
| May 15, 2024 |
Exhibit 99.2 CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position Expanding Relationship With Lifera, a Biopharma Company Owned by the PIF CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced it has entered into |
|
| May 15, 2024 |
Exhibit 4.36 Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K on the basis that the registrant customarily and actually treats that information as private or confidential and the omitted information is not material. Information that has been omitted has been noted in this document with a placeholder identified by the mark “[***]”. Dated 1 April 2024 TAKE |
|
| May 15, 2024 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Centogene N.V. (the “Company”) for the fiscal year ended December 31, 2023 (the “Report”), I, Kim Stratton, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 9 |
|
| May 15, 2024 |
Exhibit 99.9 SUCCESS FEE AGREEMENT THIS SUCCESS FEE AGREEMENT (this “Agreement”), dated as of May 12, 2024 (the “Effective Date”), among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwi |
|
| May 15, 2024 |
WRITTEN RESOLUTIONS OF THE SUPERVISORY BOARD OF CENTOGENE N.V. DATED 15, MAY 2024 Exhibit 99.6 WRITTEN RESOLUTIONS OF THE SUPERVISORY BOARD OF CENTOGENE N.V. DATED 15, MAY 2024 Resolutions of the supervisory board (the "Supervisory Board") of Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam, with address: Am Strande 7, 18055 Rostock, Germany, and trade register number: 72822872 (the "Company"). WHEREAS A. The undersigned constitute |
|
| May 15, 2024 |
Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Miguel Coego Ríos, certify that: 1.I have reviewed this Annual Report on Form 20-F of Centogene N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| May 15, 2024 |
CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights Exhibit 99.1 CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights • Reported Full Year 2023 total revenues of 2% growth at €48.5 million • Secured approximately USD 20 million – strengthening cash position and expanding relationship with Lifera, a biopharma company owned by the PIF • Positioned for strong performance in 2024, driven by new and existing Pharma business |
|
| May 15, 2024 |
VARIATION AGREEMENT NO. 1 TO TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY LICENSE AGREEMENT Exhibit 99.5 Execution version VARIATION AGREEMENT NO. 1 TO TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY LICENSE AGREEMENT THIS VARIATION AGREEMENT No. 1 (this “Agreement”) is dated 12 May 2024G. (“Effective Date”) and is made by and between: (1) GENOMICS INNOVATIONS COMPANY LIMITED, a company organized under the laws of the Kingdom of Saudi Arabia with a registered office at Building No. 3936, 6 |
|
| May 15, 2024 |
VARIATION AGREEMENT NO. 1 TO CONSULTANCY AGREEMENT Exhibit 99.4 Execution version VARIATION AGREEMENT NO. 1 TO CONSULTANCY AGREEMENT THIS VARIATION AGREEMENT NO. 1 TO CONSULTANCY AGREEMENT (this “Agreement”) is dated 12 May 2024 (“Effective Date”) and is made by and between: (1) GENOMICS INNOVATIONS COMPANY LIMITED, a company organized under the laws of the Kingdom of Saudi Arabia with a registered office at Building No. 3936, 6651 Al Nakheel Dist |
|
| May 15, 2024 |
VARIATION AGREEMENT NO. 1 TO KSA RECEIVABLES TRANSFER AGREEMENT Exhibit 99.2 Execution version VARIATION AGREEMENT NO. 1 TO KSA RECEIVABLES TRANSFER AGREEMENT THIS VARIATION AGREEMENT NO. 1 TO KSA RECEIVABLES TRANSFER AGREEMENT (this “Agreement”) is dated 12 May 2024. (“Effective Date”) and is made by and between: (1) CENTOGENE GMBH, a limited liability company incorporated under the laws of Germany, having its registered office at Am Strande 7, 18055 Rostock, |
|
| May 15, 2024 |
CLAWBACK POLICY CENTOGENE N.V. (the “Company”) Exhibit 97.1 CLAWBACK POLICY CENTOGENE N.V. (the “Company”) INTRODUCTION 1. Article 1 a. This clawback policy (this “Policy”) sets out the Company’s Clawback Policy as mandated by the SEC pursuant to the Dodd-Frank Act. This Policy (i) provides for the recoupment of certain Incentive Compensation in the event of a Financial Restatement resulting from material noncompliance with financial reporting |
|
| May 15, 2024 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Centogene N.V. (the “Company”) for the fiscal year ended December 31, 2023 (the “Report”), I, Miguel Coego Ríos, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Sect |
|
| May 15, 2024 |
AMENDMENT TO THE AWARD AGREEMENT Exhibit 4.33 AMENDMENT TO THE AWARD AGREEMENT THIS AGREEMENT IS MADE ON 20 JUNE 2023 BETWEEN 1. Kim Stratton, born on 9 July 1962 (the "Participant"); and 2. Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam (address: Am Strande 7, 18055 Rostock, Germany, trade register number: 72822872) (the "Company"). Each a "Party" and together the "Parties". WHERE |
|
| May 14, 2024 |
CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease Exhibit 99.1 CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease · CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical research · Companies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potenti |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| May 10, 2024 |
Exhibit 99.1 CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients Fueling the diagnosis of over 2,500 rare and neurodegenerative diseases, more than 300 peer-reviewed publications, and 48 pharma collaborations CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 10, 2024 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-39124 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form |
|
| May 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by c |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by |
|
| April 2, 2024 |
CENTOGENE Receives Nasdaq Non-Compliance Notice Exhibit 99.1 CENTOGENE Receives Nasdaq Non-Compliance Notice CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 2, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated March 27, 2024, from the Na |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate by |
|
| March 19, 2024 |
Exhibit 99.1 CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders · Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -Centogene N.V. (Nasdaq: CNTG |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| February 29, 2024 |
Exhibit 99.1 CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency Complete Pre-TCRα Deficiency Found to be Very Rare, Partial Form More Common Than Expected CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, February 29, 2024 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for d |
|
| February 28, 2024 |
CENTOGENE Explores Strategic Alternatives Exhibit 99.1 CENTOGENE Explores Strategic Alternatives CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 28, 2024 (GLOBE NEWSWIRE) -Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that the Company has decided to explore a range of strategic alternatives focused on sustainable |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| February 28, 2024 |
Exhibit 99.1 CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 28, 2024 (GLOBE NEWSWIRE) -Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven an |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| January 25, 2024 |
Exhibit 99.1 CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical Development CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, January 25, 2024 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life |
|
| January 24, 2024 |
Exhibit 99.1 CENTOGENE Receives French Research Tax Credit Accreditation Partners able to claim up to 30% tax relief CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, January 24, 2024 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has been recognized by the French Ministry |
|
| January 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| January 23, 2024 |
Exhibit 99.1 CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics Collaboration to accelerate research to determine role of GBA gene CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, January 23, 2024 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers |
|
| January 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive office) Indicate |
|
| January 18, 2024 |
CENTOGENE Announces Preliminary Full Year 2023 Revenue Exhibit 99.1 CENTOGENE Announces Preliminary Full Year 2023 Revenue CAMBRIDGE, Mass. And ROSTOCK, Germany and BERLIN, January 18, 2024 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced preliminary unaudited revenue for full year 2023 between approximately €48.5 million and €49.0 milli |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of December 19, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| December 19, 2023 |
CENTOGENE Announces Voting Results of Extraordinary General Meeting Exhibit 99.1 CENTOGENE Announces Voting Results of Extraordinary General Meeting CAMBRIDGE, Mass. And ROSTOCK, Germany and BERLIN, December 19, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. All voting items on |
|
| December 18, 2023 |
CENTOGENE Announces Changes in Supervisory Board Exhibit 99.1 CENTOGENE Announces Changes in Supervisory Board CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, Dec. 18, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced Andreas Busch’s and Holger Friedrich’s decision to resign from the Company’s Supervisory Board, effective Decemb |
|
| December 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of December 18, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| December 13, 2023 |
Exhibit 99.1 Press Release CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone CAMBRIDGE, Mass. And ROSTOCK, Germany, and BERLIN, December 13, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initi |
|
| December 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of December 13, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| December 1, 2023 |
WRITTEN RESOLUTIONS OF THE SUPERVISORY BOARD OF CENTOGENE N.V. DATED 29 NOVEMBER 2023 Exhibit 99.4 WRITTEN RESOLUTIONS OF THE SUPERVISORY BOARD OF CENTOGENE N.V. DATED 29 NOVEMBER 2023 Resolutions of the supervisory board (the "Supervisory Board") of Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam (address: Am Strande 7, 18055 Rostock, Germany, trade register number: 72822872) (the "Company"). WHEREAS A. The undersigned constitute the |
|
| December 1, 2023 |
WRITTEN RESOLUTIONS OF THE MANAGEMENT BOARD OF CENTOGENE N.V. DATED 29 NOVEMBER 2023 Exhibit 99.3 WRITTEN RESOLUTIONS OF THE MANAGEMENT BOARD OF CENTOGENE N.V. DATED 29 NOVEMBER 2023 Resolutions of the management board (the "Management Board") of Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam (address: Am Strande 7, 18055 Rostock, Germany, trade register number: 72822872) (the "Company"). WHEREAS A. The undersigned constitute the en |
|
| December 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of December 1, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| December 1, 2023 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the extraordinary general meeting of shareholders of Centogene N.V. (the "Company") to be held on December 18, 2023 at 10.00 a.m. CET at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "EGM"). The agenda for the EGM is as follows: 1. Opening 2. Discussion of Dutch statutory board report for |
|
| December 1, 2023 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on December 18, 2023 at 10.00 a.m. CET at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR |
|
| November 28, 2023 |
GENOMICS INNOVATIONS COMPANY LIMITED CENTOGENE N.V. dated 27 November 2023 Exhibit 99.4 Execution Version GENOMICS INNOVATIONS COMPANY LIMITED (“Company”) and CENTOGENE N.V. (“NV”) dated 27 November 2023 TECHNOLOGY TRANSFER AND INTELLECTUAL PROPERTY LICENSE AGREEMENT TABLE OF CONTENTS Clause Page 1. DEFINITIONS; INTERPRETATION 1 2. LICENSE GRANTS AND ASSOCIATED RIGHTS AND RESTRICTIONS 1 3. TECHNOLOGY TRANSFER AND USE OF DATA 4 4. INTELLECTUAL PROPERTY OWNERSHIP, PROTECTI |
|
| November 28, 2023 |
GENOMICS INNOVATIONS COMPANY LIMITED (“Company”) CENTOGENE N.V. (“NV”) dated 27 November 2023 Exhibit 99.3 Execution Version GENOMICS INNOVATIONS COMPANY LIMITED (“Company”) and CENTOGENE N.V. (“NV”) dated 27 November 2023 LABORATORY SERVICES AGREEMENT TABLE OF CONTENTS Clause Page 1. Definitions; Interpretation; Conflicts 1 2. Engagement and Scope of Authority 1 3. NV’s Obligations and Responsibilities 4 4. Company’s Responsibilities 8 5. Charges for the testing services 9 6. TAXES 10 7. |
|
| November 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of November 28, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| November 28, 2023 |
Exhibit 99.1 Press Release CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction · Lifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) |
|
| November 28, 2023 |
GENOMICS INNOVATIONS COMPANY LIMITED CENTOGENE N.V. dated 27 November 2023 Exhibit 99.2 Execution Version GENOMICS INNOVATIONS COMPANY LIMITED (“Company”) and CENTOGENE N.V. (“NV”) dated 27 November 2023 CONSULTANCY AGREEMENT related to KSA FACILITY CONTENTS Clause Page 1. Definitions; Interpretation; Conflicts 1 2. Engagement and Scope of Authority 1 3. NV’s Obligations and Responsibilities 3 4. Company’s Obligations and Responsibilities 4 5. FEES 5 6. TAXES 8 7. Standa |
|
| November 3, 2023 |
THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 99.1 THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of November 1, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the L |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of November 3, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| October 27, 2023 |
Exhibit 99.5 SUBORDINATION AGREEMENT This Subordination Agreement (the “Agreement”) is made as of October 26, 2023, by and between PHARMACEUTICAL INVESTMENT COMPANY, a closed joint stock company incorporated pursuant to the laws of the Kingdom of Saudi Arabia, with commercial registration number 1010698585, having its registered address located at Alra’idah Digital City, Building MU04, Al Nakhil D |
|
| October 27, 2023 |
VARIATION AGREEMENT TO JOINT VENTURE AGREEMENT Exhibit 99.1 Execution Copy VARIATION AGREEMENT TO JOINT VENTURE AGREEMENT THIS VARIATION AGREEMENT (this “Agreement”) is dated 23 October, 2023 and is made by and among: (1) PHARMACEUTICAL INVESTMENT COMPANY, a closed joint stock company incorporated pursuant to the laws of the Kingdom of Saudi Arabia, with commercial registration number 1010698585, having its registered address located at Alra’i |
|
| October 27, 2023 |
Exhibit 99.6 Execution Version PHARMACEUTICAL INVESTMENT COMPANY Alra’idah Digital City, Building MU04, Al Nakhil District P.O. Box 6847, Riyadh 11452 The Kingdom of Saudi Arabia October 26, 2023 Re: Right of First Offer Agreement Ladies and Gentlemen: This right of first offer agreement (this “Agreement”) is entered into by and between Pharmaceutical Investment Company, a closed joint stock compa |
|
| October 27, 2023 |
Exhibit 99.3 Execution Version PHARMACEUTICAL INVESTMENT COMPANY Alra’idah Digital City, Building MU04, Al Nakhil District, P.O. Box 6847, Riyadh 11452, The Kingdom of Saudi Arabia October 26, 2023 Centogene N.V. Am Strande 7 18055 Rostock Germany Re: Loan Agreement – Preemptive Rights Agreement Ladies and Gentlemen: This preemptive rights agreement (this “Agreement”) sets forth the agreements bet |
|
| October 27, 2023 |
Centogene N.V. Second Registration Rights Agreement October 26, 2023 Table of Contents Exhibit 99.4 Execution Version Centogene N.V. Second Registration Rights Agreement October 26, 2023 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 7 Section 3. General Resale Registration Statement 8 (a) Filing and Effectiveness of General Resale Registration Statement 8 (b) Contents of and Requirements for General Resale Registration Statement 8 (c) Obligation to |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of October 27, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| October 27, 2023 |
Exhibit 99.2 Execution Version LOAN AGREEMENT dated as of October 26, 2023 by and among CENTOGENE N.V., as Borrower, and PHARMACEUTICAL INVESTMENT COMPANY, as Lender, Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 8 Section 3. The Loan 9 (a) Generally 9 (b) The Closing 9 Section 4. Representations, Warranties and Covenants of the Borrower 10 (a) Due Organization, |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of October 10, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| October 10, 2023 |
Exhibit 99.1 Press Release CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering Incorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biology CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, October 10, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-dr |
|
| October 6, 2023 |
CENTOGENE Announces Changes in Supervisory Board Exhibit 99.1 CENTOGENE Announces Changes in Supervisory Board CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, October 6, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that Dr. Flemming Ornskov has decided to step down from his role as a member of the Supervisor |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of October 6, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indica |
|
| September 7, 2023 |
Exhibit 99.1 CENTOGENE Reports First Half 2023 Financial Results Strong Revenues and Steady Growth in Both Diagnostics and Pharma Segments Drive Sustainable Financial Performance ● First half 2023 total revenues with double-digit growth of 15.1% at €24.6 million ● Both Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 1 |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of September 7, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant’s name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| September 7, 2023 |
For the six months ended June 30 Exhibit 99.2 Centogene N.V. Unaudited consolidated statements of comprehensive loss (in EUR k) For the six months ended June 30 2023 2022 Revenue 24,624 21,389 Cost of sales 15,728 13,036 Gross profit 8,896 8,353 Research and development expenses 6,851 9,071 General administrative expenses 17,172 17,284 Selling expenses 6,699 5,192 Impairment of financial assets 496 — Gain on reversal of financial |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of September 1, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| September 1, 2023 |
Exhibit 99.1 PRESS RELEASE CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients • Results from pivotal study published in Diagnostics journal • Confirmation of utility of lyso-Gb1 (glucosylsphingosine) as a sensitive biomarker for Gaucher disease • Could predict clinical course of patients and improve personalized care CAMBRIDGE, Mass. and RO |
|
| August 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of August 31, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indica |
|
| August 31, 2023 |
Exhibit 99.1 Press Release CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, August 31, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announce |
|
| August 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of August 18, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indica |
|
| August 18, 2023 |
CENTOGENE Announces Change in Supervisory Board Exhibit 99.1 CENTOGENE Announces Change in Supervisory Board CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, August 18, 2023 – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced Berndt Modig’s decision to resign from the Company’s Supervisory Board, effective August 15, 2023. Mr. Modig’ |
|
| July 14, 2023 |
CENTOGENE Regains Compliance With Nasdaq Listing Requirements Exhibit 99.1 PRESS RELEASE CENTOGENE Regains Compliance With Nasdaq Listing Requirements CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, July 14, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has received notifications from the Nasdaq Stock Market L |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of July 14, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| July 12, 2023 |
Exhibit 99.1 PRESS RELEASE CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort Results Published in European Journal of Human Genetics Demonstrate Unprecedented Insights to Accelerate Potential Treatment Options · Inclusion of 602 patients from 47 countries represents the world’s largest and most heterogeneous Niemann-Pick type C1 disease (N |
|
| July 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of July 12, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 30, 2023 |
CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting Exhibit 99.1 CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 30, 2023 (GLOBE NEWSWIRE) – CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Annual General Meeti |
|
| June 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 30, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 27, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 27, 2023 |
CONSENT UNDER LOAN AND SECURITY AGREEMENT Exhibit 99.7 CONSENT UNDER LOAN AND SECURITY AGREEMENT THIS CONSENT UNDER LOAN AND SECURITY AGREEMENT (this “Consent”) is entered into as of June 24, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders (as defi |
|
| June 27, 2023 |
Exhibit 99.2 EXECUTION VERSION 26 June 2023 PHARMACEUTICAL INVESTMENT COMPANY and CENTOGENE N.V. JOINT VENTURE AGREEMENT 7th Floor, Tower 1, Al-Tatweer Towers King Fahad Highway P.O. Box 17411 Riyadh 11484 Saudi Arabia Tel: +966.11.207.2500 www.lw.com CONTENTS Clause Page 1. DEFINITIONS AND INTERPRETATION 1 2. INCORPORATION 13 3. THE Company and its BUSINESS 15 4. SHARE CAPITAL OF THE COMPANY 16 5 |
|
| June 27, 2023 |
Exhibit 99.6 PHARMACEUTICAL INVESTMENT COMPANY Alra’idah Digital City, Building MU04, Al Nakhil District P.O. Box 6847, Riyadh 11452 The Kingdom of Saudi Arabia [], 2023 Re: Right of First Offer Agreement Ladies and Gentlemen: This right of first offer agreement (this “Agreement”) is entered into by and between Pharmaceutical Investment Company, a closed joint stock company incorporated pursuant t |
|
| June 27, 2023 |
Exhibit 99.3 Proposed Execution Version LOAN AGREEMENT dated as of , 2023 by and among CENTOGENE N.V., as Borrower, and PHARMACEUTICAL INVESTMENT COMPANY, as Lender, Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 8 Section 3. The Loan 9 (a) Generally 9 (b) The Closing 9 Section 4. Representations, Warranties and Covenants of the Borrower 10 (a) Due Organization, V |
|
| June 27, 2023 |
Exhibit 99.4 Proposed Execution Version PHARMACEUTICAL INVESTMENT COMPANY Alra’idah Digital City, Building MU04, Al Nakhil District, P.O. Box 6847, Riyadh 11452, The Kingdom of Saudi Arabia [], 2023 Centogene N.V. Am Strande 7 18055 Rostock Germany Re: Loan Agreement – Preemptive Rights Agreement Ladies and Gentlemen: This preemptive rights agreement (this “Agreement”) sets forth the agreements be |
|
| June 27, 2023 |
Exhibit 99.1 PRESS RELEASE CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment · Joint Venture (JV) combines CENTOGENE's global leadership in multiomics with local insight of Lifera, a biopharmaceutical company wholly- |
|
| June 27, 2023 |
Centogene N.V. Second Registration Rights Agreement _____ 2023 Table of Contents Exhibit 99.5 Proposed Execution Draft CONFIDENTIAL Centogene N.V. Second Registration Rights Agreement 2023 Table of Contents Page Section 1. Definitions 1 Section 2. Rules of Construction 7 Section 3. General Resale Registration Statement 8 (a) Filing and Effectiveness of General Resale Registration Statement 8 (b) Contents of and Requirements for General Resale Registration Statement 8 (c) Oblig |
|
| June 14, 2023 |
Exhibit 99.1 PRESS RELEASE CENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 14, 2023 (GLOBE NEWSWIRE) – Centogene N.V. (Nasdaq: CNTG) (“we” or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it has rec |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 14, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 13, 2023 |
WRITTEN RESOLUTIONS OF THE SUPERVISORY BOARD OF CENTOGENE N.V. DATED MAY 23, 2023 Exhibit 99.4 WRITTEN RESOLUTIONS OF THE SUPERVISORY BOARD OF CENTOGENE N.V. DATED MAY 23, 2023 Resolutions of the supervisory board (the "Supervisory Board") of Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam (address: Am Strande 7, 18055 Rostock, Germany, trade register number: 72822872) (the "Company"). WHEREAS A. The undersigned constitute the ent |
|
| June 13, 2023 |
WRITTEN RESOLUTIONS OF THE MANAGEMENT BOARD OF CENTOGENE N.V. DATED MAY 23, 2023 Exhibit 99.3 WRITTEN RESOLUTIONS OF THE MANAGEMENT BOARD OF CENTOGENE N.V. DATED MAY 23, 2023 Resolutions of the management board (the "Management Board") of Centogene N.V., a public company with limited liability, having its corporate seat in Amsterdam (address: Am Strande 7, 18055 Rostock, Germany, trade register number: 72822872) (the "Company"). WHEREAS A. The undersigned constitute the entire |
|
| June 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 13, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 13, 2023 |
Exhibit 99.1 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on June 30, 2023 at 2.00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Extension of the period for drawing up the Dutch statutor |
|
| June 13, 2023 |
Exhibit 99.2 VOTING PROXY THE UNDERSIGNED Name : Address : acting on behalf of (only to be completed if relevant) Name : Address : (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on June 30, 2023 at 2.00 p.m. CEST at the offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amst |
|
| May 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 19, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 16, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant’s name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| May 17, 2023 |
Exhibit 99.1 CENTOGENE Reports Full Year 2022 Financial Results ● Full Year 2022 total revenues with double-digit growth of 12% at €47.5 million, in line with prior guidance ● Significant expansion of gross profit margin from 32% to 42% and ongoing cost control resulted in significant improvement of net results ● Both Pharma and Diagnostics segments positioned for strong performance in 2023, guida |
|
| May 16, 2023 |
Exhibit 13.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Centogene N.V. (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Miguel Coego Ríos, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Sect |
|
| May 16, 2023 |
Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Miguel Coego Ríos, certify that: 1.I have reviewed this Annual Report on Form 20-F of Centogene N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of |
|
| May 16, 2023 |
Exhibit 13.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 20-F of Centogene N.V. (the “Company”) for the fiscal year ended December 31, 2022 (the “Report”), I, Kim Stratton, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 9 |
|
| May 16, 2023 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-234551) pertaining to the Centogene N.V. Long-Term Incentive Plan of our report dated May 15, 2023, with respect to the consolidated financial statements of Centogene N.V. included in this Annual Report (Form 20-F) for the year ended Dec |
|
| May 16, 2023 |
LONG-TERM INCENTIVE PLAN CENTOGENE N.V. Exhibit 4.20 LONG-TERM INCENTIVE PLAN CENTOGENE N.V. INTRODUCTION Article 1 1.1This document sets out the Company's long-term incentive plan for employees, officers and other service providers who qualify as Eligible Participants. 1.2The main purposes of this Plan are: 1. to attract, retain and motivate Participants with the qualities, skills and experience needed to support and promote the growth |
|
| May 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF |
|
| May 16, 2023 |
EX-4.19 2 cntg-20221231xex4d19.htm EX-4.19 Exhibit 4.19 Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K on the basis that the registrant customarily and actually treats that information as private or confidential and the omitted information is not material. Information that has been omitted has been noted in this document with a placeholder identified b |
|
| May 16, 2023 |
Exhibit 12.1 CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Kim Stratton, certify that: 1.I have reviewed this Annual Report on Form 20-F of Centogene N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the c |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 4, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate b |
|
| May 4, 2023 |
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT Exhibit 99.1 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of April 30, 2023, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the L |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-1757097 NOTIFICATION OF LATE FILING (Check one): ¨ Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR For Period Ended: December 31, 2022 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Fo |
|
| April 28, 2023 |
CENTOGENE Receives Nasdaq Non-Compliance Notice Exhibit 99.1 Press Release CENTOGENE Receives Nasdaq Non-Compliance Notice CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 28, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG) (“Centogene”, “we”, or the “Company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that it received a notification letter dated April 24, 20 |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of April 28, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of April 26, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| April 26, 2023 |
Exhibit 99.1 CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline Enabling Rapid and Reliable Diagnosis and Research of Rare Genetic Diseases Around the World · CENTOGENE’s FilterTool aims to fuel rapid, reliable analysis for diagnosis and research of rare genetic diseases by significantly reducing time- and |
|
| April 12, 2023 |
Exhibit 99.1 PRESS RELEASE CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases · Aims to resolve patient diagnostic odyssey, often spanning years and multiple misdiagnoses before accurate diagnosis · Combines cutting-edge technology and streamlined CE-IVD bioinformatics pipeline with the CENTOGENE Bio |
|
| April 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of April 12, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| April 11, 2023 |
Exhibit 99.1 PRESS RELEASE CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders · The global market access and expansion partnership, initially established in 2015, aims to provide an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) · Diagnosis plays a critical role in gui |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of April 11, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 28, 2023 |
CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, March 28, 2023 Exhibit 99.1 CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, March 28, 2023 - Centogene N.V. (“CENTOGENE”) and IQVIA have formed a collaboration to improve health outcomes for rare disease patients by accelerating and de-risking clinical development and increasing access to genetic testing. Through combined capabilities in real-world data and scalable partnering solutions, this collaboration will |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of March 28, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of March 14, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of March 9, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| March 9, 2023 |
CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma Exhibit 99.1 Press Release CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, March 9, 2023 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the appointment of Ian Rentsch as Chief Commercial Officer |
|
| February 21, 2023 |
Exhibit 99.1 Press Release In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) · FTD is a rare and rapidly progressing neurodegenerative disease caused by multiple hereditary factors, including mutations in the progranulin (GRN) gene · The observational EFRONT study is increasing the number of sites to expa |
|
| February 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of February 21, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| February 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of February 7, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| February 7, 2023 |
CENTOGENE Regains Compliance With Nasdaq Listing Requirements EX-99.1 2 dp188460ex9901.htm EXHIBIT 99.1 Exhibit 99.1 CENTOGENE Regains Compliance With Nasdaq Listing Requirements CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 07, 2023 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, received confirmation on February 6, 2023 from the Nasdaq Stock Mar |
|
| January 30, 2023 |
CENTOGENE Announces Executive Appointment EX-99.1 2 dp187746ex9901.htm EXHIBIT 99.1 Exhibit 99.1 CENTOGENE Announces Executive Appointment CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, January 30, 2023 - Centogene N.V. (the “Company”) (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that Prof. Peter Bauer, M.D., the Company’s Chief Medical and Genomic Of |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of January 30, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| January 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of January 19, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| January 19, 2023 |
CENTOGENE Announces Departure From Executive Team EXHIBIT 99.1 CENTOGENE Announces Departure From Executive Team CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, January 19, 2023 - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced that Dr. Florian Vogel, Chief Process Officer (CPO) and a member of the management board of Centogene GmbH, has decided to |
|
| January 10, 2023 |
6-K 1 dp1867446k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of January 10, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of prin |
|
| January 10, 2023 |
Exhibit 99.1 Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics Combining expertise to advance precision medicine, while enabling efficient and timely insights into the diagnosis of rare diseases and hereditary cancer around the world SOUTH SAN FRANCISCO, Calif. CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, – January 1 |
|
| January 9, 2023 |
EX-99.1 2 dp186778ex9901.htm EXHIBIT 99.1 Exhibit 99.1 CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics Working together to deliver data-driven, informative genotyping answers to accelerate and de-risk drug discovery, development, and commercialization for Parkinson’s disease (PD) · The Rostock International Parkinson's Disease (ROPAD) St |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of January 9, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indica |
|
| January 9, 2023 |
6-K 1 dp1867786k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of January 9, 2023 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of princ |
|
| January 9, 2023 |
EX-99.1 2 dp186736ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development Leveraging Rare Disease Insights Powered by the CENTOGENE Biodatabank and Centralized Multiomic Laboratories in Clinical Trials MORRISVILLE, N.C., and CAMBRIDGE, Mass., ROSTOCK, Germany, and BERLIN, January 9, 2023 — Premier |
|
| December 22, 2022 |
CENTOGENE Reports Second Quarter and First Half 2022 Financial Results EX-99.1 2 cntg-20220630xex99d1.htm EX-99.1 Exhibit 99.1 CENTOGENE Reports Second Quarter and First Half 2022 Financial Results CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, December 22nd, 2022 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced unaudited financial results for the sec |
|
| December 22, 2022 |
For the three months ended June 30 Exhibit 99.2 Centogene N.V. Unaudited consolidated statements of comprehensive loss (in EUR k) ? ? ? ? ? ? ? ? ? ? ? ? ? For the three months ended June 30 For the six months ended June 30 ? ? ? ? 2022 2021* (Revised) 2022 ? 2021* (Revised) Revenue ? ? 11,198 9,209 21,389 ? 19,002 Cost of sales ? ? 6,586 6,617 13,036 ? 12,825 Gross profit ? ? 4,612 2,592 8,353 ? 6,177 Research and development expe |
|
| December 22, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 ? For the date of December 22, 2022 ? Commission File Number 001-39124 ? Centogene N.V. (Translation of registrant?s name into English) ? Am Strande 7 18055 Rostock Germany (Address of principal executi |
|
| December 22, 2022 |
Exhibit 99.3 Risk Factors In the course of conducting our business operations, we are exposed to a variety of risks, some of which are inherent in our industry and others of which are more specific to our own businesses. The discussion below addresses risks of which we are currently aware, that could affect our businesses, results of operations and financial condition and make an investment in the |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of December 16, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| December 16, 2022 |
CENTOGENE Receives Nasdaq Non-Compliance Notice EX-99.1 2 dp185697ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release CENTOGENE Receives Nasdaq Non-Compliance Notice CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, has received notification from the Nasdaq Stock Market LLC Listing Qua |
|
| November 21, 2022 |
6-K 1 dp1845676k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of November 21, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of pri |
|
| November 21, 2022 |
EX-99.1 2 dp184567ex9901.htm EXHIBIT 99.1 Exhibit 99.1 PRESS RELEASE CENTOGENE Announces Changes to Supervisory Board, Including Appointment of Mary Sheahan Adding significant financial expertise with an impressive track record in value creation CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, November 21, 2022 (GLOBE NEWSWIRE – Centogene N.V. (Nasdaq: CNTG), the essential life science partner f |
|
| November 3, 2022 |
CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network Exhibit 99.1 CENTOGENE Press Release CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network ? Company?s launch of Biodata Network offers new portfolio of data-driven solutions ? Collaboration with BC Platforms increases access to data-driven genomic insights via Global Data Partner Network, BCRQUEST.com ? Tranche of 80,000 genetic sequences made accessible online for research and dr |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of November 3, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indic |
|
| October 3, 2022 |
Exhibit 99.1 Press Release CENTOGENE Reaches 12,500 Patient Milestone in World?s Largest Observational Study on Parkinson?s Disease Genetics Working together with Denali Therapeutics to accelerate data-driven precision medicine for the PD community ? Rostock International Parkinson's Disease (ROPAD) Study aims to characterize the genetics of PD to establish a better understanding of the disease pr |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of October 3, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indica |
|
| September 1, 2022 |
CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September EX-99.1 2 dp179631ex9901.htm EXHIBIT 99.1 Exhibit 99.1 CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, September 1, 2022 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced its investment and partnering c |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of September 1, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| July 15, 2022 |
For the three months ended March 31 Exhibit 99.2 Centogene N.V. Unaudited interim condensed consolidated statements of comprehensive loss for the three months ended March 31, 2022 and 2021 (in EUR k) ? ? ? ? ? ? ? ? ? ? For the three months ended March 31 ? ? Note ? 2022 2021* Revenue 4, 5 ? 10,327 9,981 Cost of sales ? ? 6,450 6,208 Gross profit ? ? 3,877 3,773 Research and development expenses ? ? 4,614 4,335 General administrativ |
|
| July 15, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 ? For the date of July 15, 2022 ? Commission File Number 001-39124 ? Centogene N.V. (Translation of registrant?s name into English) ? Am Strande 7 18055 Rostock Germany (Address of principal executive o |
|
| July 15, 2022 |
CENTOGENE Reports First Quarter 2022 Financial Results On Track for FY 2022 Guidance EX-99.1 2 cntg-20220331xex99d1.htm EX-99.1 Exhibit 99.1 CENTOGENE Reports First Quarter 2022 Financial Results On Track for FY 2022 Guidance ● Q1 2022 revenue rises 3% to €10.3 million ● Completed phase out of COVID-19 Business segment in Q1 2022 ● Positioning Pharma and Diagnostics for post-COVID recovery and growth in 2022 and beyond ● Reaffirms FY 2022 guidance of 15-20% revenue growth CAMBRIDG |
|
| July 15, 2022 |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS EX-99.3 4 cntg-20220331xex99d3.htm EX-99.3 Exhibit 99.3 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion of our financial condition and results of operations should be read in conjunction with Centogene N.V.’s unaudited interim condensed consolidated financial statements as of March 31, 2022 and December 31, 2021 and for the three month |
|
| June 27, 2022 |
Exhibit 99.1 MEDIA RELEASE CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022: Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the voting results of the Company?s Annual General Meeting. Shareho |
|
| June 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 27, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 27, 2022 |
Exhibit 99.2 MEDIA RELEASE CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer Interim CFO Miguel Coego Rios appointed as Managing Director and permanent CFO CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, |
|
| June 13, 2022 |
EX-99.1 2 dp174985ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease Working together on the world’s first treatment that targets the underlying causes of pyruvate kinase (“PK”) deficiency in children under the age of 18 · Expanded collaboration to include Phase 3 ACTI |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 13, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 7, 2022 |
RESOLUTIONS OF THE SUPERVISORY BOARD CENTOGENE N.V. Effective date: May 31, 2022 EX-99.4 5 dp174639ex9904.htm EXHIBIT 99.4 EXHIBIT 99.4 RESOLUTIONS OF THE SUPERVISORY BOARD CENTOGENE N.V. Effective date: May 31, 2022 This document is to certify the adoption of the resolutions reflected below by the supervisory board (the "Supervisory Board") of Centogene N.V. (the "Company"). With respect to the resolutions set out below, except as expressly noted otherwise, the undersigned do |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of June 7, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| June 7, 2022 |
EXHIBIT 99.1 CONVENING NOTICE This is the convening notice for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on June 22, 2022 at 5:00 p.m. CEST at Sheraton Amsterdam Airport Hotel and Conference Centre, Schiphol Boulevard 101, 1118 BG Schiphol, the Netherlands (the "AGM"). The agenda for the AGM is as follows: 1. Opening 2. Discussion of Dutch statutory bo |
|
| June 7, 2022 |
RESOLUTIONS OF THE MANAGEMENT BOARD CENTOGENE N.V. Effective date: May 31, 2022 EX-99.3 4 dp174639ex9903.htm EXHIBIT 99.3 EXHIBIT 99.3 RESOLUTIONS OF THE MANAGEMENT BOARD CENTOGENE N.V. Effective date: May 31, 2022 The following resolutions of the management board (the "Management Board") of Centogene N.V. (the "Company") are passed. WHEREAS A. The undersigned constitute the entire Management Board. B. There are no regulations and/or other rules adopted by any of the Company' |
|
| June 7, 2022 |
EXHIBIT 99.2 VOTING PROXY THE UNDERSIGNED Name: Address: acting on behalf of (only to be completed if relevant) Name: Address: (the "Principal"). DECLARES AS FOLLOWS 1. The Principal hereby registers for the annual general meeting of shareholders of Centogene N.V. (the "Company") to be held on June 22, 2022 at 5:00 p.m. CEST at Sheraton Amsterdam Airport Hotel and Conference Centre, Schiphol Boule |
|
| May 25, 2022 |
EX-99.1 2 dp1738309901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework CE-marked clinical decision support platform enables laboratories to provide best-in-class diagnostics of genetic diseases · CentoCloud, CENTOGENE’s cloud-based Software as a Service (SaaS) platf |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 25, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 23, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| May 23, 2022 |
Exhibit 99.1 CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics Newly established WGS recommendations published in the European Journal of Human Genetics ? Collaborative initiative leverages CENTOGENE?s differentiated diagnostic expertise with testing performed in over 650,000 individuals globally ? Recommendations provid |
|
| May 19, 2022 |
CENTOGENE to Present at the H.C. Wainwright Global Investment Conference EX-99.1 2 dp173470ex9901.htm EXHIBIT 99.1 Exhibit 99.1 CENTOGENE to Present at the H.C. Wainwright Global Investment Conference CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced that Company management will present in the |
|
| May 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 19, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of May 3, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicate b |
|
| May 3, 2022 |
CENTOGENE Announces Departure From Executive Team Exhibit 99.1 CENTOGENE Announces Departure From Executive Team CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, May 2 2022? Centogene N.V. (Nasdaq: CNTG), the commercial-staged essential biodata life science partner for rare and neurodegenerative diseases, today announced that Volkmar Weckesser, Ph.D., Chief Information Officer (CIO) and a member of the management board of Centogene N.V., is ste |
|
| April 28, 2022 |
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally EX-99.1 2 dp171772ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Press Release CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases · CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare meta |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of April 28, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 31, 2022 |
EX-4.14 3 cntg-20211231xex4d14.htm EX-4.14 Exhibit 4.14 English Summary Framework agreement on the performance of confirmatory diagnostics for SARS-CoV-2 This Agreement (hereinafter referred to as the “Service Agreement”) is entered into between: 21Dx GmbH, with the address at Kreillerstraße 210, 81825 München, Germany (“Customer”) and Centogene GmbH (“CENTOGENE”), a company incorporated in accord |
|
| March 31, 2022 |
Exhibit 13.2 ? CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ? In connection with the Annual Report on Form 20-F of Centogene N.V. (the ?Company?) for the fiscal year ended December 31, 2021 (the ?Report?), I, Rene Just, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section |
|
| March 31, 2022 |
Exhibit 13.1 ? CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 ? In connection with the Annual Report on Form 20-F of Centogene N.V. (the ?Company?) for the fiscal year ended December 31, 2021 (the ?Report?), I, Kim Stratton, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Secti |
|
| March 31, 2022 |
EX-4.12 2 cntg-20211231xex4d12.htm EX-4.12 Exhibit 4.12 English Summary Service Agreement This Service Agreement (hereinafter referred to as the “Service Agreement”) is entered into based on the tender award dated April 29, 2021 between: Free State of Bavaria, Germany, represented by the Bavarian State Office for Health and Food Safety with address at Eggenreuther Weg 43, 91058 Erlangen, Germany ( |
|
| March 31, 2022 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* Exhibit 12.2 CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, René Just, certify that: 1.I have reviewed this Annual Report on Form 20-F of Centogene N.V.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circ |
|
| March 31, 2022 |
Consent of Ernst & Young GmbH Wirtschaftsprüfungsgesellschaft.* EX-15.1 9 cntg-20211231xex15d1.htm EX-15.1 Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-234551) pertaining to the Centogene N.V. Long-Term Incentive Plan of our report dated March 31, 2022, with respect to the consolidated financial statements of Centogene N.V. included in this Ann |
|
| March 31, 2022 |
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.* Exhibit 12.1 ? CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 ? I, Kim Stratton, certify that: ? 1.I have reviewed this Annual Report on Form 20-F of Centogene N.V.; ? 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 20-F Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 30, 2022 |
? Exhibit 99.1 CENTOGENE Reports Fourth Quarter and Fiscal Year 2021 Financial Results - Full Year 2021 Total Revenue Growth of 48%, and 11% in Core Business Segments, Exceeds Guidance - Focus on Pharma and Diagnostics to Position for Strong Performance in 2022 - Closed $62 million Financing Round and on Track to Exit COVID-19 Business - Management to Host Conference Call at 2 p.m. CET/8 a.m. ET T |
|
| March 30, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 6-K ? REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 ? For the date of March 30, 2022 ? Commission File Number 001-39124 ? Centogene N.V. (Translation of registrant?s name into English) ? Am Strande 7 18055 Rostock Germany (Address of principal executive |
|
| March 24, 2022 |
EX-99.1 2 dp169775ex9901.htm EXHIBIT 99.1 Exhibit 99.1 MEDIA RELEASE CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 24, 2022 (GLOBE NEWSWIRE) - Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced today that C |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of March 24, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 23, 2022 |
CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022 Exhibit 99.1 PRESS RELEASE CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022 CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, March 23, 2022 (GLOBE NEWSWIRE) ? Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced that it will issue its fina |
|
| March 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of March 23, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of March 17, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indicat |
|
| March 17, 2022 |
CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer Exhibit 99.1 PRESS RELEASE CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer ? In November 2019, CENTOGENE first announced the signing of a data access and collaboration agreement to discover and validate novel genetic and biochemical targets for the potential development of new therapies for rare diseases ? New research phase aims to substantiate earlier results |
|
| March 11, 2022 |
NL:CNTG / Centogene NV / TVM Life Science Innovation I L.P. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Centogene N.V. (Name of Issuer) Common Shares, €0.12 par value per share (Title of Class of Securities) N1976T109 (CUSIP Number) Stefan Fischer TVM Capital Ottostrasse 4 80333 Munich, Germany (49) 89998992-48 (Name, Address and Telephone Number of Person Au |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the date of February 22, 2022 Commission File Number 001-39124 Centogene N.V. (Translation of registrant's name into English) Am Strande 7 18055 Rostock Germany (Address of principal executive offices) Indi |
|
| February 22, 2022 |
EXHIBIT 99.1 MEDIA RELEASE CENTOGENE Announces Voting Results of Extraordinary General Meeting CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, February 22, 2022 (GLOBE NEWSWIRE) ?Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, today announced the voting results of the Company?s Extraordinary G |
